ReviewCurrent allergy and asthma reports2015
The Complex Type 2 Endotype in Allergy and Asthma: From Laboratory to Bedside.
Review in Current allergy and asthma reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 84 citations in OpenAlex.
- A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma.Respiratory research · 2016Trial
- Review
- Immune endotypes in tuberculosis: Keys to decoding disease complexity.Journal of internal medicine · 2026Review
- Predicting diagnostic gene biomarkers in allergic asthma.Medicine · 2026Article
- Epicutaneous Staphylococcus aureus initiates cross-tissue IL-36R signaling for neutrophilic lung inflammation in a model of the atopic march.Cell reports · 2025Article
- Endotype-driven decisions in choosing a biologic for airway diseases.Frontiers in allergy · 2025Review
- Exploring the Interplay between Asthma and Hemoglobinopathies: A Comprehensive Review.Journal of clinical medicine · 2024Review
- Effect of Hyssop (Tanaffos · 2024Article
- Transgenic overexpression of α7 integrin in smooth muscle attenuates allergen-induced airway inflammation in a murine model of asthma.FASEB bioAdvances · 2022Article
- Exploration of induced sputum BIRC3 levels and clinical implications in asthma.BMC pulmonary medicine · 2022Article
- Recent insights in the role of biomarkers in severe asthma management.Frontiers in medicine · 2022Review
- IL-36 Cytokines: Their Roles in Asthma and Potential as a Therapeutic.Frontiers in immunology · 2022Review
- Review
- New Insights into the Role of PD-1 and Its Ligands in Allergic Disease.International journal of molecular sciences · 2021Review
- Serum IgE Predicts Difference of Population and Allergens in Allergic Diseases: Data from Weifang City, China.Mediators of inflammation · 2021Article
- Biomarkers for diagnosis and prediction of therapy responses in allergic diseases and asthma.Allergy · 2020Review
- An endothelial microRNA-1-regulated network controls eosinophil trafficking in asthma and chronic rhinosinusitis.The Journal of allergy and clinical immunology · 2020Article
- Revisiting Late-Onset Asthma: Clinical Characteristics and Association with Allergy.Journal of asthma and allergy · 2020Review
- Mimicking Antigen-Driven Asthma in Rodent Models-How Close Can We Get?Frontiers in immunology · 2020Review
- Precision medicine and phenotypes, endotypes, genotypes, regiotypes, and theratypes of allergic diseases.The Journal of clinical investigation · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Better management of allergic diseases needs a sharpened understanding of disease heterogeneity and mechanisms in relation to clinically significant outcomes. Phenotypes describing observable clinical and morphologic characteristics and unique responses to treatment have been developed; however, they do not relate to disease mechanisms. Recently, extended heterogeneous and disease-related metabolic, inflammatory, immunological, and remodeling pathways have been described, and reproducible patterns are defined as disease endotypes. An endotype might consist of several intricated mechanisms that cannot be clearly separated into "pure single molecular mechanism" thus being a "complex endotype." The description of an endotype may rely on biomarkers, which can be the signature of a complex underlying pathway or a key molecule associated with or directly playing a role in a particular disease endotype. The Th2 type inflammation can be defined as a complex endotype in asthma and linked to mechanisms of disease development and response to treatment and to disease outcomes such as exacerbations and remodeling. The type 2 complex endotype in allergies and asthma includes innate lymphoid cells, T helper 2 cells, tissue eosinophilia, and IgE production. Currently, emerging endotype-driven strategies in asthma, particularly the development of biologicals that target a single molecular pathway, are being focused for solving individualized clinical problems on disease outcomes. Progress is also being made for endotyping rhinitis, chronic rhinosinusitis, and atopic dermatitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.